Respiratory syncytial virus prefusion fusion protein and seasonal influenza viral antigens (RSV PreF and Flu antigens)

The target "RSV prefusion F protein and seasonal influenza viral antigens" refers to a composite set of viral surface glycoproteins utilized in the development of combination vaccines to prevent major respiratory infections. The Respiratory Syncytial Virus (RSV) component is the fusion (F) protein stabilized in its prefusion conformation (PreF), which is the primary target for potent neutralizing antibodies that block the virus from merging with host cell membranes [3, 5, 6]. The seasonal influenza component typically consists of hemagglutinin (HA) and occasionally neuraminidase (NA) antigens from multiple circulating strains, including Influenza A (H1N1 and H3N2) and Influenza B (Victoria and Yamagata lineages) [1, 4, 17]. These antigens function by inducing the host immune system to produce neutralizing antibodies that prevent viral attachment, entry, and release [8, 13, 14]. This multi-antigen approach is designed to provide broad, seasonal protection against the leading causes of lower respiratory tract disease, particularly in high-risk populations such as older adults and young children [2, 11, 18].

Other names

RSV PreF and Influenza HA/NARSV-Flu combination antigensRSV F protein and seasonal flu antigensRespiratory syncytial virus and seasonal influenza antigens

Induction of neutralizing antibodies against the RSV prefusion F protein and influenza hemagglutinin/neuraminidase to prevent viral attachment, membrane fusion, and viral release.